Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities
PHASE2CompletedINTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
February 28, 1997
Study Completion Date
October 31, 2002
Conditions
Colorectal Neoplasm
Interventions
DRUG
2-Fluoro-2-deoxyglucose
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001568 - Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities | Biotech Hunter | Biotech Hunter